Nereid Therapeutics is discovering new disease treatments using proprietary state-of-the-art technologies for generating, visualizing, and measuring liquid-liquid phase separation and the resulting biomolecular condensates. Nereid applies leading expertise in soft matter physics and cell biology to pioneer completely new ways to fight intractable diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/16/20 | $50,000,000 | Series A |
Apple Tree Partners | undisclosed |
